GPC pulls Orplatna NDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GPC Biotech will resubmit an NDA for Orplatna (satraplatin) for treatment of hormone-refractory prostate cancer after overall survival data from an ongoing trial become available, likely next year, the Princeton, N.J. company announces July 30. The decision to withdraw the application follows a July 24 Oncologic Drugs Advisory Committee recommendation that FDA await overall survival data before deciding whether or not to approve the novel platinum compound. GPC anticipates overall survival data from the SPARC trial within six months. The firm had requested accelerated approval based on a composite progression-free survival endpoint...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.